If this box remains here for more than 30 seconds, click this link to try again.
Products & Services »
Marketing Management » Patient Advocacy
Download FREE Excerpt
66 Info Graphics
36 Data Graphics
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
Biopharmaceutical; Biotech; Manufacturing; Clinical Research; Diagnostic; Pharmaceutical; Health Care; Medical Device; Communications; Laboratories
Acceleron Pharma; Agendia; Alnylam Pharmaceuticals; Amicus Therapeutics; AveXis; AVROBIO; Biogen; Bionical Emas; Blue Earth Diagnostics; CRISPR Therapeutics; Daiichi Sankyo; Dermira; Grifols; GlaxoSmithKline ; Horizon Pharma; Incyte; Ipsen; Janssen; Johnson & Johnson; Lexicon Pharmaceuticals; Mallinckrodt; Milestone Pharmaceuticals; MSD; NexGen Healthcare Communications; OTSUKA; Reata Pharmaceuticals; Retrophin; Sage Therapeutics; Sanofi; Shire; Spark Therapeutics; Takeda Pharmaceuticals; Theravance; Ultragenyx; Wave Life Sciences
Best Practices, LLC engaged 38 leaders supporting patient advocacy at 35 biopharmaceutical companies through a benchmarking survey. More than 70% of benchmark partners are at the director level. At least 70% of benchmark partners are from the United States.
Data in this research is segmented on the basis of reporting structure to offer a clear understanding of the impact of organizational decisions on patient advocacy trends. Research data is presented into the following segments: Total Benchmark Class (N=38), Reports to Commercial (N=10), Reports to Medical Affairs (N=9), Reports to Government and Corporate Affairs (N=13) and Reports to C-Suite (N=6).
Key topics covered in this report include: